PURPOSE: The insulin-like growth factor axis plays an important role in fibrogenesis. However, little is known about mannose-6-phosphate/Insulin-like growth factor-II receptor (M6P/IGF-IIR) expression during fibrosis. When expressed preferentially on fibrogenic cells, this receptor may be used to selectively deliver drugs to these cells. METHODS: We investigated M6P/IGF-IIR expression in livers of bile duct-ligated (BDL) rats and in renal vascular walls of renin transgenic TGR(mRen2)27 rats. Both models are characterized by fibrogenic processes. Furthermore, we studied whether drug delivery via M6P/IGF-II-receptor-mediated uptake is possible in fibroblasts. RESULTS: M6P/IGF-IIR mRNA expression was investigated 3, 7 and 10 days after BDL. At all time-points hepatic M6P/IGF-IIR expression was significantly increased compared to healthy controls. Moreover, immunohistochemical staining revealed that alpha-sma-positive cells were M6P/IGF-IIR-positive. In kidneys of TGR(mRen2)27 rats, the number of M6P/IGF-IIR-positive arteries per microscopic field was increased 5.5 fold over healthy controls. To examine whether M6P/IGF-IIRs could be used as a port of entry for drugs, we coupled mycophenolic acid (MPA) to mannose-6-phosphate-modified human serum albumin (M6PHSA). M6PHSA-MPA inhibited 3T3-fibroblast proliferation dose-dependently, which was reversed by co-incubation with excess M6PHSA, but not by HSA. CONCLUSIONS: M6P/IGF-IIRs are expressed by fibrogenic cells and may be used for receptor-mediated intracellular delivery of the antifibrogenic drug MPA.
PURPOSE: The insulin-like growth factor axis plays an important role in fibrogenesis. However, little is known about mannose-6-phosphate/Insulin-like growth factor-II receptor (M6P/IGF-IIR) expression during fibrosis. When expressed preferentially on fibrogenic cells, this receptor may be used to selectively deliver drugs to these cells. METHODS: We investigated M6P/IGF-IIR expression in livers of bile duct-ligated (BDL) rats and in renal vascular walls of renin transgenic TGR(mRen2)27 rats. Both models are characterized by fibrogenic processes. Furthermore, we studied whether drug delivery via M6P/IGF-II-receptor-mediated uptake is possible in fibroblasts. RESULTS: M6P/IGF-IIR mRNA expression was investigated 3, 7 and 10 days after BDL. At all time-points hepatic M6P/IGF-IIR expression was significantly increased compared to healthy controls. Moreover, immunohistochemical staining revealed that alpha-sma-positive cells were M6P/IGF-IIR-positive. In kidneys of TGR(mRen2)27 rats, the number of M6P/IGF-IIR-positive arteries per microscopic field was increased 5.5 fold over healthy controls. To examine whether M6P/IGF-IIRs could be used as a port of entry for drugs, we coupled mycophenolic acid (MPA) to mannose-6-phosphate-modified human serum albumin (M6PHSA). M6PHSA-MPA inhibited 3T3-fibroblast proliferation dose-dependently, which was reversed by co-incubation with excess M6PHSA, but not by HSA. CONCLUSIONS: M6P/IGF-IIRs are expressed by fibrogenic cells and may be used for receptor-mediated intracellular delivery of the antifibrogenic drug MPA.
Authors: David R Nelson; Zhengkun Tu; Consuelo Soldevila-Pico; Manal Abdelmalek; Haizhen Zhu; Yi Ling Xu; Roniel Cabrera; Chen Liu; Gary L Davis Journal: Hepatology Date: 2003-10 Impact factor: 17.425
Authors: L Beljaars; G Molema; D Schuppan; A Geerts; P J De Bleser; B Weert; D K Meijer; K Poelstra Journal: J Biol Chem Date: 2000-04-28 Impact factor: 5.157
Authors: Rick Greupink; Hester I Bakker; Catharina Reker-Smit; Anne-miek van Loenen-Weemaes; Robbert-Jan Kok; Dirk K F Meijer; Leonie Beljaars; Klaas Poelstra Journal: J Hepatol Date: 2005-06-04 Impact factor: 25.083
Authors: P J de Bleser; P Jannes; S C van Buul-Offers; C M Hoogerbrugge; C F van Schravendijk; T Niki; V Rogiers; J L van den Brande; E Wisse; A Geerts Journal: Hepatology Date: 1995-05 Impact factor: 17.425
Authors: M M van den Eijnden; J J Saris; R J de Bruin; E de Wit; W Sluiter; T L Reudelhuber; M A Schalekamp; F H Derkx; A H Danser Journal: Arterioscler Thromb Vasc Biol Date: 2001-06 Impact factor: 8.311
Authors: Marike Marjolijn van Beuge; Jai Prakash; Marie Lacombe; Eduard Post; Catharina Reker-Smit; Leonie Beljaars; Klaas Poelstra Journal: Pharm Res Date: 2011-03-26 Impact factor: 4.200
Authors: Werner I Hagens; Adriana Mattos; Rick Greupink; Alie de Jager-Krikken; Catharina Reker-Smit; Annemiek van Loenen-Weemaes; I Annette S H Gouw; Klaas Poelstra; Leonie Beljaars Journal: Pharm Res Date: 2007-03 Impact factor: 4.200
Authors: Marike Marjolijn van Beuge; Jai Prakash; Marie Lacombe; Eduard Post; Catharina Reker-Smit; Leonie Beljaars; Klaas Poelstra Journal: PLoS One Date: 2013-02-18 Impact factor: 3.752